Disc Medicine reports positive Phase 3 results for bitopertin in erythropoietic protoporphyria

Disc Medicine announced that its Phase 3 APOLLO trial of bitopertin met every prespecified primary and secondary endpoint. The study, which enrolled 183 patients, showed a 41.4% drop in whole‑blood protoporphyrin IX and a 12.2‑hour increase in monthly pain‑free light exposure. The company said it will file a new drug application with the FDA before the close of 2026, with an agency decision anticipated around mid‑2027.

The resubmission could lead to the first approved therapy for erythropoietic protoporphyria, opening a market of roughly 20,000 U.S. patients and generating revenue that the company projects at $35 million in 2027 and $144 million in 2028. The news also lifted the share price sharply, providing immediate upside for investors.

  • 1The APOLLO trial enrolled 183 adult and adolescent patients with erythropoietic protoporphyria.
  • 2Bitopertin produced a 41.4% reduction in whole‑blood metal‑free protoporphyrin IX versus placebo.
  • 3Patients receiving bitopertin experienced an average increase of 12.2 hours per month of pain‑free light exposure.
  • 4The company plans to submit a new drug application to the FDA by the end of 2026.
  • 5A regulatory decision is expected around mid‑2027.
  • 6Shares rose about 60% after the topline results were released.

Sources